Recent developments highlight Tevogen Bio's strategic acquisition efforts, AI platform progress, and Nasdaq compliance challenges.

• Tevogen Bio is advancing strategic acquisition plans with potential to add $100 million in annual revenue [N3].
• The company signed a letter of intent to evaluate an MSO acquisition, which positively impacted its stock [N4].
• Tevogen.AI's PredicTcell model is nearing completion and the company has begun commercial readiness work as of April 2026 [N5].
• The board is evaluating a potential one-time special cash dividend to shareholders [N6].
• The company is aligning its long-term stock-based incentive program with company milestones including revenue [N7].
• Tevogen received Nasdaq deficiency notices in April 2026 for not meeting minimum market value and publicly held shares requirements, with compliance deadlines in October 2026 [S2].

The company is advancing AI-driven immunotherapy development with the near completion of its PredicTcell model and has begun commercial readiness work. Strategic acquisition plans with potential to add significant annual revenue and alignment of stock-based incentives with company milestones indicate focused growth initiatives. The evaluation of a potential special cash dividend reflects attention to shareholder value. These factors contribute to a positive operational momentum.

Tevogen Bio faces financial challenges including a low current ratio of 0.33 and zero cash equivalents as of the latest reporting period, indicating liquidity constraints. The company reported a net loss and negative EPS for the quarter ended June 30, 2026. It has received Nasdaq deficiency notices for not meeting minimum market value and publicly held shares requirements, with risk of delisting if compliance is not regained. These factors pose risks to financial stability and market presence.

Tevogen Bio's moat is based on its integration of AI-driven technology platforms such as Tevogen.AI to enhance immunotherapy development and clinical trial acceleration, combined with its proprietary ExacTcell pipeline. The company's strategic acquisition plans aim to broaden its product offerings and revenue streams, potentially strengthening its competitive position in the biotechnology sector. Its leadership team includes experienced executives with deep industry knowledge, supporting operational execution.

• Nasdaq Listing Compliance Risk: The company received notices in April 2026 for failing to meet Nasdaq's minimum market value and publicly held shares requirements, with compliance deadlines in October 2026. Failure to regain compliance could lead to delisting, negatively impacting share liquidity and price.
• Liquidity and Financial Performance Risk: As of June 30, 2026, the company had a current ratio of 0.33 and zero cash equivalents as of December 31, 2025, indicating limited liquidity. The company reported a net loss of $5.76 million and negative EPS, which may affect operational sustainability.
• Operational Execution Risk: The company's strategic acquisition plans and AI platform commercialization require successful execution. Delays or failures in these initiatives could impact growth and financial performance.

• Tevogen Bio Holdings Inc. is a Delaware corporation with its principal executive offices in Warren, New Jersey.
• The company is listed on The Nasdaq Stock Market under the ticker TVGN and has warrants under ticker TVGNW.
• Tevogen Bio's board consists of six directors divided into three classes with staggered three-year terms.
• Key executives include Dr. Ryan Saadi as CEO and Chairperson, Kirti Desai as CFO, and Dr. Neal Flomenberg as Chief Scientific Officer and Global R&D Lead.
• The company underwent a 1-for-50 reverse stock split effective March 6, 2026.
• As of April 28, 2026, the company had 4,187,505 shares outstanding.
• The company has an Audit Committee with members meeting SEC and Nasdaq independence and financial literacy requirements.
• Tevogen Bio is engaged in biotechnology with initiatives including AI-driven immunotherapy development and clinical trial acceleration.
• The company launched Tevogen.AI, an AI-driven platform to accelerate clinical trial participation and enhance its ExacTcell pipeline.
• Tevogen.AI's PredicTcell model is nearing completion and the company has begun commercial readiness work as of April 2026.
• Tevogen Bio is advancing strategic acquisition plans with potential to add $100 million in annual revenue and has signed a letter of intent to evaluate an MSO acquisition.
• The company is aligning its long-term stock-based incentive program with company milestones including revenue.
• The company is evaluating a potential one-time special cash dividend to shareholders.
• Financial snapshot as of June 30, 2026, shows current assets of $2,009,260 and current liabilities of $6,150,584, resulting in a current ratio of 0.33 and a cash ratio of 0.
• Net income for the quarter ended June 30, 2026, was a loss of $5,761,940 with basic and diluted EPS of -$1.52 per share.
• The company had zero cash and equivalents as of December 31, 2025.
• Tevogen Bio received Nasdaq deficiency notices in April 2026 for not meeting minimum market value and publicly held shares requirements, with compliance deadlines in October 2026.
• The company intends to monitor market value and consider options to regain Nasdaq compliance but faces risk of delisting if requirements are not met.
• The company has publicly disclosed risk factors including the risk of Nasdaq delisting and the impact on liquidity and share price if delisted.